For millions of people living with severe depression, standard treatments offer little relief. Antidepressants, therapy, electroconvulsive therapy — many have tried them all, and still the darkness remains. A new clinical trial is offering real hope for this group, showing that a small surgically implanted device that stimulates the vagus nerve can produce lasting improvements even in the most treatment-resistant cases.
A Last Resort That Finally Works
The RECOVER trial, led by researchers at Washington University School of Medicine in St. Louis, followed nearly 500 patients across 84 locations in the United States. These were not mild or moderate depression cases. On average, participants had lived with depression for 29 years and had already tried approximately 13 different treatments — including electroconvulsive therapy and transcranial magnetic stimulation — without success.
“We believe the sample in this trial represents the sickest treatment-resistant depressed patient sample ever studied in a clinical trial,” said lead author Charles Conway, MD, director of the WashU Medicine Treatment Resistant Mood Disorders Center.
How the Device Works
The therapy involves placing a small device under the skin of the chest. This device sends carefully timed electrical pulses along the left vagus nerve — a major communication pathway that runs from the brainstem down through the neck and into the chest and abdomen, connecting the brain with the heart, lungs, and digestive system.
Stimulating this nerve influences the brain circuits involved in mood regulation. The vagus nerve has long been recognised as a target for neurological and psychiatric conditions; it was first approved by the FDA for epilepsy and later for depression. What this new research shows is just how durable those benefits can be.
The Results: Lasting Improvement
The findings, published in January 2026 in the International Journal of Neuropsychopharmacology, are striking:
- About 69% of patients receiving active treatment showed meaningful improvement — defined as at least a 30% reduction in symptoms — within one year.
- Of those who improved at 12 months, more than 80% had maintained or increased their gains by the two-year mark.
- Among patients who had a substantial response (50% or greater symptom reduction) at one year, 92% were still doing better at two years.
- Roughly one in five treated patients achieved full remission after two years, functioning normally without significant depressive symptoms.
- Even many patients who did not respond in the first year went on to show benefits by year two.
“These results are highly atypical,” said Conway, “as most studies of markedly treatment-resistant depression have very poor sustainability of benefit, certainly not at two years.”
Why This Matters for the Vagus Nerve Community
Depression affects approximately one in five American adults at some point in their lifetime. Up to a third of those people develop treatment-resistant depression — a condition that does not respond adequately to standard medications or therapies. For this group, the consequences are severe: impaired functioning, lost relationships, hospitalisation, and a significantly elevated risk of suicide.
Until now, options for this population have been limited. This trial offers evidence that stimulating the vagus nerve — a pathway that has attracted growing interest across a range of health conditions — may provide a sustainable path forward where other treatments have failed.
Access and Coverage
One practical goal of the RECOVER trial is to generate the evidence needed for the U.S. Centers for Medicare and Medicaid Services (CMS) to consider covering the therapy. Cost remains a significant barrier for many patients. If CMS approves coverage, private insurers would likely follow, opening access to a far wider population.
The device is manufactured by LivaNova USA, Inc. FDA approval for vagus nerve stimulation for depression is already in place — what the trial is helping to establish is the long-term evidence base that payors require before extending coverage.
A Turning Point in Treatment-Resistant Depression
For people who have spent decades cycling through treatments and still not found relief, the message from this research is meaningful: the vagus nerve may hold an answer that conventional psychiatry has not. As research into vagus nerve stimulation continues to expand across depression, inflammation, heart health, and beyond, this trial adds to a growing body of evidence that the vagus nerve sits at the centre of some of the body’s most important regulatory systems.
If you or someone you know has been living with treatment-resistant depression, speak with a qualified healthcare provider about whether vagus nerve stimulation may be an appropriate option to explore.
